-
The "involution" of generic drugs has intensified, and innovative drugs will bring a blue ocean of development to pharmaceutical companies
Time of Update: 2022-08-15
. On July 15, Sihuan Pharmaceutical announced that the company intends to propose the sale of some or all of its generic drugs and other non-core traditional medicine businesses that have not met the company's performance expectations or are not in line with the company's long-term strategic goals due to changes in the pharmaceutical industry.
-
The market size of liver disease drugs is expected to reach 100 billion, and domestic pharmaceutical companies are expected to become the winners
Time of Update: 2022-08-15
[Pharmaceutical Network Market Analysis] July 28 is the twelfth World Hepatitis Day . Hepatitis is an inflammation of the liver caused by viruses, bacteria, parasites, chemical poisons, alcohol, auto
-
The global transdermal drug delivery market is expected to reach 200 billion yuan, and my country still has considerable room for development
Time of Update: 2022-08-15
, a subsidiary of MicroPort Group, to jointly invest in the establishment of a joint venture company for pharmaceutical equipment and give full play to their respective With the advantages and resources in the fields of transdermal drug delivery systems, new drug development and pharmaceutical research, we will realize complementary advantages and carry out in-depth cooperation in the field of polypeptide microneedle transdermal drug delivery .
-
The pharmaceutical companies that plan to win the seventh batch of Guocai have reported good news, and many stock prices have risen accordingly
Time of Update: 2022-08-15
44 yuan/box) The company announced that its two subsidiaries planned to win the bid for the seventh batch of national centralized drug procurement.
-
Behind the accelerated withdrawal of Chinese patent medicines from medical insurance, what should Chinese medicine companies do?
Time of Update: 2022-08-15
In addition, compared with proprietary Chinese medicines, the industry generally believes that Chinese herbal decoction pieces and formula granules are less pressured by medical insurance to control costs and have growth potential .
-
Overview of China's hospital drug market in the first quarter of 2022
Time of Update: 2022-08-15
Figure 4 National-Hospital Drug Market-Scale and Growth Rate of 30 Provinces and Cities (MAT2022Q1) Overview of China's Hospital Drug Market In MAT2022Q1, the total sales of China's hospital drug market reached 976 Bn, a year-on-year increase of 2.
-
This pharmaceutical stock hit a new high in 6 months, and its net profit increased by more than 15% in the first half of the year
Time of Update: 2022-08-15
91 million yuan, a year-on-year increase of 50% Among them, in the first half of 2022 alone, the company's research and development expenses reached 83.
-
General Administration of Customs: Strictly prevent the introduction of acute severe hepatitis in children of unknown cause
Time of Update: 2022-08-15
(Headquarters CCTV reporter Sun Shuwen and Kong Lingwen) In response to reports of unexplained acute severe hepatitis cases in children in many countries around the world, the General Administration of Customs has recently made arrangements for health and quarantine related work at customs ports across the country to prevent the spread of the epidemic into China .
-
Pharmaceutical growth is still very rigid, it is recommended to pay attention to the three main lines and these individual stocks
Time of Update: 2022-08-15
;Focusing on the development strategy of "reinforcing the foundation, extending the breakthrough, and innovating and exploring", consolidate the three core products and break through the functional health care category; provide solutions according to the needs of the market and customers, enhance the ability and innovation vitality of digital organizations, and continuously improve profitability ability and operating efficiency, and achieve healthy and healthy development of the company .
-
"14th Five-Year Plan" for Drug Regulatory Network Security and Informatization Construction
Time of Update: 2022-08-15
On May 11, the State Food and Drug Administration issued the "14th Five-Year Plan for Drug Regulatory Network Security and Informatization Construction" . The plan mentioned that the construction of
-
On August 8, 2 pharmaceutical stocks hit record highs in intraday trading
Time of Update: 2022-08-15
. On the news, Yaokang Biology recently replied to investors on the interactive platform that the company is currently focusing on the research and development, production, sales and related technical services of experimental animal mouse models, and for new businesses such as life science downstream and non-human primates.
-
A number of blockbuster new drugs have been approved for clinical use, and domestic anti-tumor drugs are about to usher in the harvest period
Time of Update: 2022-08-15
-AS269 conjugate (ARX305) "Drug Clinical Trial Approval Notice", agreeing to carry out clinical trials of this product as a single drug in patients with advanced tumors For example, on July 12, Zhejiang Pharmaceutical issued an announcement stating that its subsidiary Zhejiang Xinma Bio-Pharmaceutical Co.
-
Under the pressure of centralized procurement and price reduction, how should generic drugs break through?
Time of Update: 2022-08-15
Behind this, it is actually driven by the centralized procurement policy, generic drug companies The cost for marketing has been gradually compressed, and the pricing power of drugs has shifted from the sales side to the production side For example, in the first batch of domestic procurement, Xinlitai, which lost its bid for its core product, clopidogrel hydrogen sulfate tablets, saw a sharp drop in the year-on-year growth rate of non-net profit in 2019 and 2020, respectively, by 54.
-
Only 6 imported drugs are to be selected for the seventh batch of centralized procurement. Do multinational pharmaceutical companies choose to "lie down"?
Time of Update: 2022-08-15
For example, Huizhi's lipid-lowering drug Lipitor (atorvastatin calcium tablets), which was transferred to the out-of-hospital market after the first batch of national centralized procurement failed to win the bid, the company stated in its 2021 financial report that the growth of new channels will partly This offset the decline in sales in hospitals due to volume purchases .
-
13 pharmaceutical companies sprint for IPO, but these companies have no products listed and no profits
Time of Update: 2022-08-15
It is reported that Suzhou Huyun plans to invest a total of 450 million yuan of raised funds this time, which will all be used for innovative drug R&D projects, innovative drug R&D and production base construction projects and supplementary working capital .
-
With the advancement of new medical reforms such as centralized procurement, such pharmaceutical companies may gradually withdraw from the market
Time of Update: 2022-08-15
The industry believes that the realization of a vertically integrated industry chain of "API + preparation" will help Chinese generic drug companies to reduce costs and improve profit So, how should pharmaceutical companies transform?
-
The latest news on the policy of online sales of prescription drugs!
Time of Update: 2022-08-15
In 2018, the "Measures for the Supervision and Administration of Online Drug Sales (Draft for Comment)" stated that if the online drug sellers are drug retail chain enterprises, they are not allowed to sell prescription drugs and drugs with special national management requirements through the Internet; sell to individual consumers.
-
Chain pharmacies are about to enter the "10,000-store era", and a large number of single drugstores are facing reshuffle
Time of Update: 2022-08-15
Industry analysts believe that in the second half of the year, the major chain pharmacies will speed up their staking, and the "10,000-store era" is just around the corner The size of the store is a demonstration of the core competitiveness of pharmaceutical retail enterprises.
-
The market prospect of cell therapy equipment is considerable, and domestic enterprises are constantly making efforts in the direction of automation
Time of Update: 2022-08-15
[Pharmaceutical Network Market Analysis] Cell therapy represented by stem cells and immune cells is attracting widespread attention . In 2021, two domestic CAR-T cell therapy drugs, Akilenxe Injectio
-
The State Food and Drug Administration approved the registration of 212 medical devices in April 2022
Time of Update: 2022-08-12
, Ltd. National Mechanical Note 20223080433 On May 16, the State Food and Drug Administration issued the "Announcement on Approval and Registration of 212 Medical Device Products (April 2022) (No. 38 of 2022)" .
